The Global Doxorubicin Market Set to Grow at 6.8% CAGR, Reaching USD 1.81 Billion by 2034

Rising Prevalence of Cancer Worldwide and Continuous Quest for More Effective Treatment Options Driving Sales of Doxorubicin: Fact.MR Study

Fact.MR, a market research and competitive intelligence provider, in its updated industry report reveals that the global doxorubicin market is approximated at US$ 940.5 million in 2024 and has been calculated to increase at a CAGR of 6.8% through 2034. According to information published by Our World in Data, around 10 million people die due to cancer each year across the globe.

Cases of cancer are increasing rapidly across the globe. Unhealthy dietary habits and busy and stressful lifestyles are some of the factors leading to the development of cancer tumors. Respective governments across the globe are undertaking several initiatives to increase the awareness of cancer and its treatment. The majority of governments worldwide are offering supportive reimbursement polices for cancer treatment.

Industry leaders are joining hands with research institutions for the development of advanced cancer treatment solutions. Such collaborations are set to offer improved cancer therapeutics. Israel is one of the top countries in providing advanced cancer treatment.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7303

Key Takeaways from the Market Study:

• The global doxorubicin market is forecasted to reach US$ 1.81 billion by 2034.
• The United States is estimated to hold 87.2% of the North American market share in 2024.
• Sales of doxorubicin in South Korea are projected to rise at a CAGR of 7.4% from 2024 to 2034.
• The market in India is calculated at US$ 49.9 million for 2024.
• Revenue from lyophilized doxorubicin powder is projected to reach US$ 1.07 billion by 2034.

“Ongoing advancements in the field of cancer treatment such as integration of nanocomposites set to increase the profits of doxorubicin manufacturers,” says a Fact.MR analyst.

Regional Analysis

North America and Europe are key markets for doxorubicin suppliers. These regions are witnessing high cases of cancer, leading to alarming mortality rates.

• According to the Cancer Statistics 2023 report by PubMed, the United States witnessed around 1,958,310 new cancer cases in the year.
• According to the World Health Organization, around 1.9 million deaths take place each year in Europe due to cancer.

Asia Pacific is considered a fast-growing market for doxorubicin. The ongoing advancements in healthcare infrastructure and the biopharma industry are expected to offer lucrative opportunities for doxorubicin manufacturers. The surge in medical tourism is also expected to boost the doxorubicin market growth in the Asia Pacific.

Doxorubicin Industry News:

Key players in the doxorubicin market are actively investing in research and development to introduce novel cancer treatments, enhancing their market position and revenue share. To expand their product offerings, companies are also leveraging strategic initiatives such as mergers, acquisitions, and collaborations.

• In 2024, Johnson & Johnson completed the acquisition of Ambrx, a move aimed at reinforcing its commitment to innovation in prostate cancer treatment. This acquisition is expected to drive the development of next-generation antibody drugs and targeted oncologic therapeutics, further solidifying Johnson & Johnson’s presence in the oncology sector.

Leading Players Driving Innovation in the Doxorubicin Market

Key industry participants like Pfizer Inc.; Reddy’s Laboratories Ltd.; Changzhou Kinyond Pharmaceutical Co. Ltd.; Janssen-Cilag Pty Limited; Meiji Seika Pharma Co. Ltd.; Cipla Limited; Hikma Thymoorgan Pharmazie GmbH; Synbias Pharma AG; Novartis International AG; Teva Pharmaceutical Industries Ltd.; Accord Healthcare Ireland Ltd.; Cadila Healthcare Limited; MicroBiopharm Japan Co. Ltd.; TTY Biopharm Company Limited etc. are driving the doxorubicin industry.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=7303

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global doxorubicin market, presenting historical demand data (2019 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights on the market based on formulation (lyophilized doxorubicin powder, doxorubicin solutions), cancer type (breast cancer, prostate cancer, ovarian cancer, lung cancer, bladder cancer, stomach cancer, leukemia, others), and distribution channel (hospital pharmacies, retail pharmacies, e-Commerce), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Check out More Related Studies Published by Fact.MR Research:

Triple negative breast cancer treatment market is estimated to reach US$ 670.5 million in 2024. The market is analyzed to climb to a value of US$ 1.04 billion by the end of 2034, expanding at a CAGR of 4.6% over the next ten years.

Anti-cancer drugs market size is on track to reach US$ 198,957.9 million in 2024. The market is poised for consistent growth, with a promising compound annual growth rate (CAGR) of 7.5% projected through 2034. This expansion is expected to elevate the market to a substantial valuation of US$ 411,789.3 million by 2034.

Cancer biomarkers market is projected to reach US$ 34 Billion by 2032 and grow at a CAGR of 12%. Breast cancer segment held the largest share in 2021.

Cancer immunotherapy market is set to garner US$ 159.2 billion in revenue in 2024, according to Fact.MR, a market research and intelligence provider. Worldwide demand for cancer immunotherapies is projected to increase at a CAGR of 10% and reach a market value of US$ 412.8 billion by 2034.

Cancer supportive care product market is projected to increase from a value of US$ 35.47 billion in 2024 to US$ 68.93 billion by the end of 2034. Worldwide sales of cancer-supportive care products are forecasted to rise at a CAGR of 6.9% from 2024 to 2034.

Contact:US Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583Sales Team : [email protected]Follow Us: LinkedIn | Twitter | Blog